ADMA Biologics, Inc. (ADMA)
10.68
-0.27
(-2.47%)
USD |
NASDAQ |
Oct 23, 16:00
10.68
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Enterprise Value : 2.475B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.475B |
| October 22, 2026 | 2.535B |
| October 21, 2026 | 2.549B |
| October 20, 2026 | 2.599B |
| October 19, 2026 | 2.563B |
| October 16, 2026 | 2.475B |
| October 15, 2026 | 2.486B |
| October 14, 2026 | 2.398B |
| October 13, 2026 | 2.391B |
| October 12, 2026 | 2.362B |
| October 09, 2026 | 2.402B |
| October 08, 2026 | 2.396B |
| October 07, 2026 | 2.353B |
| October 06, 2026 | 2.362B |
| October 05, 2026 | 2.346B |
| October 02, 2026 | 2.258B |
| October 01, 2026 | 2.306B |
| September 30, 2026 | 2.328B |
| September 29, 2026 | 2.312B |
| September 28, 2026 | 2.348B |
| September 25, 2026 | 2.182B |
| September 24, 2026 | 2.213B |
| September 23, 2026 | 2.254B |
| September 22, 2026 | 2.279B |
| September 21, 2026 | 2.210B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.121B |
| September 17, 2026 | 2.085B |
| September 16, 2026 | 2.073B |
| September 15, 2026 | 2.008B |
| September 14, 2026 | 2.128B |
| September 11, 2026 | 2.148B |
| September 10, 2026 | 2.184B |
| September 09, 2026 | 2.197B |
| September 08, 2026 | 2.218B |
| September 04, 2026 | 2.236B |
| September 03, 2026 | 2.227B |
| September 02, 2026 | 2.211B |
| September 01, 2026 | 2.170B |
| August 31, 2026 | 2.184B |
| August 28, 2026 | 2.173B |
| August 27, 2026 | 2.204B |
| August 26, 2026 | 2.238B |
| August 25, 2026 | 2.258B |
| August 24, 2026 | 2.220B |
| August 21, 2026 | 2.285B |
| August 20, 2026 | 2.267B |
| August 19, 2026 | 2.333B |
| August 18, 2026 | 2.218B |
| August 17, 2026 | 2.173B |
| August 14, 2026 | 2.202B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vericel Corp. | 2.108B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
| Emergent BioSolutions, Inc. | 766.90M |
| Exelixis, Inc. | 15.39B |
| Akebia Therapeutics, Inc. | 207.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.82M |
| Revenue (Quarterly) | 124.40M |
| Total Expenses (Quarterly) | 86.57M |
| EPS Diluted (Quarterly) | 0.1642 |
| Gross Profit Margin (Quarterly) | 69.31% |
| Profit Margin (Quarterly) | 30.40% |
| Earnings Yield | 6.60% |
| Operating Earnings Yield | 8.46% |
| Normalized Earnings Yield | 6.654 |